Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, Scotiabank Analyst Says

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target upped by stock analysts at Scotiabank from $51.00 to $53.00 in a report released on Friday, Benzinga reports. The firm presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price indicates a potential upside of 18.12% from the stock’s current price.

A number of other research analysts also recently weighed in on AGIO. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Finally, Raymond James reissued an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Stock Up 1.0 %

AGIO stock opened at $44.87 on Friday. The firm has a market cap of $2.55 billion, a PE ratio of -6.90, a P/E/G ratio of 0.47 and a beta of 0.75. The business has a 50 day moving average of $44.62 and a 200-day moving average of $42.13. Agios Pharmaceuticals has a 12-month low of $20.40 and a 12-month high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.51) earnings per share. On average, research analysts expect that Agios Pharmaceuticals will post 7.54 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Atria Investments Inc raised its stake in Agios Pharmaceuticals by 47.4% in the third quarter. Atria Investments Inc now owns 10,628 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 3,418 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Agios Pharmaceuticals by 19.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 39,090 shares of the biopharmaceutical company’s stock worth $1,737,000 after acquiring an additional 6,320 shares during the last quarter. Oak Ridge Investments LLC lifted its holdings in shares of Agios Pharmaceuticals by 14.6% during the 3rd quarter. Oak Ridge Investments LLC now owns 40,378 shares of the biopharmaceutical company’s stock worth $1,794,000 after acquiring an additional 5,142 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Agios Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,942 shares of the biopharmaceutical company’s stock worth $486,000 after acquiring an additional 4,272 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.